A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304
Trial details
- Registry ID
- NCT02656303
- Phase
- Phase 2
The FDA approved Umbralisib (TGR-1202) on 5 Feb 2021.
Drug identity checked against registry records
Also recorded as TGR-1202; UKONIQ
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2021-02-05Day | Umbralisib | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA213176", "applicant_as_listed_by_fda": "TG THERAPS", "brand_names": ["UKONIQ"], "active_ingredients": ["UMBRALISIB TOSYLATE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20210205", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |